Respuesta :
- In order to diagnose, track, and forecast posttransplant lymphoproliferative disease (PTLD) in immunocompromised graft recipients, Epstein-Barr virus (EBV) DNA quantification is being introduced into standard medical practice.
What is posttransplant lymphoproliferative disorder and what are its effects?
- Posttransplant lymphoproliferative disorder(PTLD) is an aggressive tumor that almost always contains EBV DNA in the neoplastic cells.
- It can be fatal if it is not identified and treated straight away.
- Implementing EBV load assays by real-time PCR is made easier by validated methods, available reagents, and automated tools.
- EBV DNA levels can be used to determine the clinical state of EBV-related neoplasia in either whole blood or plasma.
- Low virus loads are common in healthy transplant recipients, while high EBV loads are significantly linked to either existing or future PTLD.
- Simultaneous laboratory testing and histopathologic analysis of lesional tissue aid in the interpretation of slight increases in viral load.
- Circulating EBV levels are a useful, noninvasive technique for assessing the success of treatment since they reflect changes in tumor load in repeated samples.
- Serial testing enables early clinical intervention to stop the progression of frank PTLD in high-risk patients.
- A key method for treating PTLD is restoring T cell immunity against EBV, and innovative EBV-directed treatments are being investigated to prevent virus-driven neoplasia.
To learn more about Epstein-barr virus visit:
https://brainly.com/question/28145321
#SPJ4
